FindTrial
Sign In

Axitinib (VEGF-TKI)

DRUG2 trials

Sponsors

University of California, San Francisco, Peking University First Hospital

Conditions

Clear Cell Renal Cell CarcinomaImmunotherapyMetastatic Clear Cell Renal Cell CarcinomaRadiation TherapyRecurrent Clear Cell Renal Cell CarcinomaRenal Cancer MetastaticStage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8

Phase 2

Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery
TerminatedNCT04370509
University of California, San FranciscoClear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Recurrent Clear Cell Renal Cell Carcinoma +2
Start: 2021-02-09End: 2025-02-28Updated: 2025-11-19
SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC
RecruitingNCT06889649
Peking University First HospitalImmunotherapy, Radiation Therapy, Renal Cancer Metastatic +1
Start: 2019-01-01End: 2028-02-20Target: 30Updated: 2025-03-21

Related Papers

Efficacy and safety of SABR/partial‑SABR combined with axitinib and toripalimab in recurrent or metastatic renal cell carcinoma: Preliminary results from a prospective phase 2 trial
Oncology Letters2025-06-02